Pliant Therapeutics Inc Asset Resilience Ratio
Pliant Therapeutics Inc asset resilience ratio. Pliant Therapeutics Inc (PLRX) has an Asset Resilience Ratio of 70.16% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See PLRX days of operational coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Pliant Therapeutics Inc (2018–2025)
Asset resilience ratio of Pliant Therapeutics Inc from 2018 to 2025. This chart shows how Pliant Therapeutics Inc's Asset Resilience Ratio has changed over time. Read Pliant Therapeutics Inc (PLRX) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Pliant Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Pliant Therapeutics Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $133.22 Million | 70.16% |
| Total Liquid Assets | $133.22 Million | 70.16% |
Asset Resilience Insights
- Very High Liquidity: Pliant Therapeutics Inc maintains exceptional liquid asset reserves at 70.16% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Pliant Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Pliant Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Pliant Therapeutics Inc Asset Resilience Ratio by Year (2018–2025)
Pliant Therapeutics Inc asset resilience ratio by year from 2018 to 2025. The table below shows the annual Asset Resilience Ratio data for Pliant Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 64.60% | $145.50 Million | $225.23 Million | -7.08pp |
| 2024-12-31 | 71.68% | $284.54 Million | $396.95 Million | -12.48pp |
| 2023-12-31 | 84.16% | $431.01 Million | $512.15 Million | -0.70pp |
| 2022-12-31 | 84.85% | $297.50 Million | $350.61 Million | +17.53pp |
| 2021-12-31 | 67.32% | $148.93 Million | $221.22 Million | -9.15pp |
| 2020-12-31 | 76.48% | $226.01 Million | $295.53 Million | +62.23pp |
| 2019-12-31 | 14.25% | $16.97 Million | $119.06 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $66.53 Million | -- |
About Pliant Therapeutics Inc
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform c… Read more